Array
(
[a_id] => 438487
[c_id] => 35678
[r_id] => 1744
[rr_id] => 1744
[m_id] => 1
[s_id] => 25646
[id_id] => 0
[v_id] => 30043
[loc_id] => 0
[ft_id] => 0
[a_classification] => news
[a_layout] => 1
[a_headline] => Prostate Cancer Therapy ADT Found To Boost Alzheimer’s And Dementia Risk
[a_sheadline] =>
[a_slug] => prostate-cancer-therapy-adt-found-boost-alzheimers-dementia-risk-438487
[a_subheadline] =>
[a_summary] => Androgen Deprivation Therapy (ADT) might contribute to the onset of Alzheimer's disease or dementia, says anorher study.
[a_article] =>
A study in 2015 again revealed the disturbing finding Androgen Deprivation Therapy (ADT), an antihormone therapy which is the most effective treatment yet for prostate cancer, might also increase the risk of Alzheimer's disease or dementia.
Prostate cancer remains the most common nonskin cancer among men in the United States and the second leading cause of cancer death in American men. ADT (or hormone therapy) has been shown to dramatically reduce the spread and progression of prostate cancer but it does carry risks.
A new study published this week in JAMA supports this initial finding, and provides further evidence ADT might indeed be linked to a higher likelihood of being diagnosed with Alzheimer's disease or dementia. It found that among elderly patients with prostate cancer, ADT exposure was associated with subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10 years.
Alone or as part of multimodal therapy, ADT reduces the likelihood of cancer progression and mortality in high-risk localized, locally advanced, recurrent, or metastatic prostate cancer. Despite these benefits, it’s been found ADT could have long-term effects on bone, sexual, and cardiovascular health. These factors influence prostate cancer-related quality of life, functional status, and healthcare.
Scientists note the possible association between ADT exposure and cognitive dysfunction represents a growing concern. The study from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA involved 154,089 men.
Of this total, 62,330 received ADT within two years of their prostate cancer diagnosis. The other 91,759 did not. Of the patients with prostate cancer who received ADT, 13 percent were later diagnosed with Alzheimer's disease compared to 9 percent who did not receive ADT.
For dementia, the number of prostate cancer patients that received ADT diagnosed with dementia jumped to 22 percent of patients as against to 16 percent that did not receive ADT. The lifetime risk for Alzheimer's dementia for men overall is 12 percent, according to data from the Framingham Heart Study.
“Our results suggest that clinicians need to raise their awareness about potential long-term cognitive effects of hormone therapy and discuss these risks with their patients,"
Dr. Jayadevappa is a research associate professor of Geriatrics and senior fellow in the Leonard Davis Institute of Health Economics.
ADT works by reducing levels of androgens (the male hormones in the body) to stop them from stimulating prostate cancer cells to grow. It’s typically used in patients that have an advanced state of the disease, when the cancer has metastasized, or in those with a high risk of recurrence after their initial treatment.
A study in 2015 again revealed the disturbing finding Androgen Deprivation Therapy (ADT), an antihormone therapy which is the most effective treatment yet for prostate cancer, might also increase the risk of Alzheimer's disease or dementia.
Prostate cancer remains the most common nonskin cancer among men in the United States and the second leading cause of cancer death in American men. ADT (or hormone therapy) has been shown to dramatically reduce the spread and progression of prostate cancer but it does carry risks.
A new study published this week in JAMA supports this initial finding, and provides further evidence ADT might indeed be linked to a higher likelihood of being diagnosed with Alzheimer's disease or dementia. It found that among elderly patients with prostate cancer, ADT exposure was associated with subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10 years.
Alone or as part of multimodal therapy, ADT reduces the likelihood of cancer progression and mortality in high-risk localized, locally advanced, recurrent, or metastatic prostate cancer. Despite these benefits, it’s been found ADT could have long-term effects on bone, sexual, and cardiovascular health. These factors influence prostate cancer-related quality of life, functional status, and healthcare.
Scientists note the possible association between ADT exposure and cognitive dysfunction represents a growing concern. The study from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA involved 154,089 men.
Of this total, 62,330 received ADT within two years of their prostate cancer diagnosis. The other 91,759 did not. Of the patients with prostate cancer who received ADT, 13 percent were later diagnosed with Alzheimer's disease compared to 9 percent who did not receive ADT.
New research reveals Alzheimer's most notorious risk factors, many of which can be prevented.Photo courtesy of Shutterstock
For dementia, the number of prostate cancer patients that received ADT diagnosed with dementia jumped to 22 percent of patients as against to 16 percent that did not receive ADT. The lifetime risk for Alzheimer's dementia for men overall is 12 percent, according to data from the Framingham Heart Study.
“Our results suggest that clinicians need to raise their awareness about potential long-term cognitive effects of hormone therapy and discuss these risks with their patients,"
Dr. Jayadevappa is a research associate professor of Geriatrics and senior fellow in the Leonard Davis Institute of Health Economics.
ADT works by reducing levels of androgens (the male hormones in the body) to stop them from stimulating prostate cancer cells to grow. It’s typically used in patients that have an advanced state of the disease, when the cancer has metastasized, or in those with a high risk of recurrence after their initial treatment.
The study also revealed that individuals who quit smoking, regardless of age, can achieve a life expectancy similar to non-smokers within approximately 10 years after quitting, and nearly half of this benefit can be noticed within just three years.
Researchers found that a combination of genetics and environmental factors reduces longevity in dementia patients. The same combination may shorten the lives of their siblings even without dementia.
The suicide rates increase substantially when air pollution rises, and the effect was particularly strong in the elderly, with older women 2.5 times more at risk than other groups.
While mental stress is commonly acknowledged in connection with grief, it is crucial to understand that grief can also present physical symptoms, including illnesses, fatigue, pain, and sleep disturbances.
The use of antidepressants, particularly fluoxetine, could affect the development of the prefrontal cortex of the infant's brain, potentially raising the risk of mental health disorders later in their life.
Researchers have developed smart earrings that could continuously monitor a person's earlobe temperature. The innovation known as Thermal Earring could also be potentially used to track signs of ovulation, stress, eating, and exercise.
The researchers made the interesting finding using a trial involving patients with a rare genetic condition called Alpha-1 antitrypsin deficiency (AATD).
People infected with the flu were more likely to need hospital care in the following year for common neurologic conditions than people who had the SARS-CoV2 infection.
Among women with a history of pregnancy complications, those who achieved or maintained high heart health after pregnancy were at a similar risk for heart disease as women without adverse pregnancy outcomes and good cardiovascular health, the study stated.
The study published in the journal BMJ indicated that individuals with hypermobile joints had a 30% higher chance of not fully recovering from COVID-19 and experiencing persistent fatigue associated with long COVID.
The studies showed that COVID antigens lingered in the blood up to 14 months after infection and more than two years in tissue samples of people who had the infection.
Those individuals who receive a COVID-19 vaccine during the first half of their menstrual cycle are more likely to experience cycle length changes than those receiving a vaccine in the latter half.
A study in 2015 again revealed the disturbing finding Androgen Deprivation Therapy (ADT), an antihormone therapy which is the most effective treatment yet for prostate cancer, might also increase the risk of Alzheimer's disease or dementia.
Prostate cancer remains the most common nonskin cancer among men in the United States and the second leading cause of cancer death in American men. ADT (or hormone therapy) has been shown to dramatically reduce the spread and progression of prostate cancer but it does carry risks.
A new study published this week in JAMA supports this initial finding, and provides further evidence ADT might indeed be linked to a higher likelihood of being diagnosed with Alzheimer's disease or dementia. It found that among elderly patients with prostate cancer, ADT exposure was associated with subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10 years.
Alone or as part of multimodal therapy, ADT reduces the likelihood of cancer progression and mortality in high-risk localized, locally advanced, recurrent, or metastatic prostate cancer. Despite these benefits, it’s been found ADT could have long-term effects on bone, sexual, and cardiovascular health. These factors influence prostate cancer-related quality of life, functional status, and healthcare.
Scientists note the possible association between ADT exposure and cognitive dysfunction represents a growing concern. The study from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA involved 154,089 men.
Of this total, 62,330 received ADT within two years of their prostate cancer diagnosis. The other 91,759 did not. Of the patients with prostate cancer who received ADT, 13 percent were later diagnosed with Alzheimer's disease compared to 9 percent who did not receive ADT.
New research reveals Alzheimer's most notorious risk factors, many of which can be prevented.Photo courtesy of Shutterstock
For dementia, the number of prostate cancer patients that received ADT diagnosed with dementia jumped to 22 percent of patients as against to 16 percent that did not receive ADT. The lifetime risk for Alzheimer's dementia for men overall is 12 percent, according to data from the Framingham Heart Study.
“Our results suggest that clinicians need to raise their awareness about potential long-term cognitive effects of hormone therapy and discuss these risks with their patients,"
Dr. Jayadevappa is a research associate professor of Geriatrics and senior fellow in the Leonard Davis Institute of Health Economics.
ADT works by reducing levels of androgens (the male hormones in the body) to stop them from stimulating prostate cancer cells to grow. It’s typically used in patients that have an advanced state of the disease, when the cancer has metastasized, or in those with a high risk of recurrence after their initial treatment.
